CD28 and neoplasm: While the rationale for the initial incorporation of CD28 as a co‐stimulatory molecule in a second‐generation CAR for NK cells was less well‐defined,88 it has recently been validated to result in enhanced CAR‐NK cell persistence and sustained anti‐tumour cytotoxicity.89